CRISPR/Cas9基因编辑技术在泌尿系统肿瘤研究中的应用  

Application of CRISPR/Cas9 genome editing technology in urologic tumors

作　　者：高鑫 张淑芳[1] Gao Xin;Zhang Shufang(Central Laboratory,Central South University Xiangya School of Medicine Affiliated Haikou Hospital,Hainan Haikou 570208,China)

机构地区：[1]中南大学湘雅医学院附属海口医院中心实验室,海南海口570208

出　　处：《现代肿瘤医学》2018年第19期3133-3137,共5页Journal of Modern Oncology

基　　金：国家自然科学基金(编号:81460450;81760465);2017年海南省创新团队资助项目(编号:2017CXTD010)

摘　　要：CRISPR/Cas9(clustered regularly interspaced short palindromic repeats/CRISPR-associated nuclease 9)基因编辑技术是源于细菌和古细菌介导抵御外源性遗传物质入侵的获得性免疫防御系统,可以实现对基因组的定点修饰。相对于传统的基因编辑系统,该系统具有设计简单、易操作、成本低廉和更加高效等优势,广泛应用于肿瘤学研究,包括肿瘤分子机制的研究、筛选肿瘤细胞耐药相关基因及肿瘤治疗等多方面。本文就CRISPR/Cas9在泌尿系统肿瘤研究中的应用进展进行综述。CRISPR/Cas9 （clustered regularly interspaced short palindromic repeats/CRISPR- associated nuclease 9） genome editing technology is a new tool developed based on acquired immunity of bacteria and archaea that confers resistance to foreign genetic elements. This technology has been used to modify genes at a special region. Compared with traditional genome editing technology, CRISPR/Cas9 system is simpler - designing, easier operating, less cost and more efficient. Currently, CRISPR/Cas9 technology has been widely applied to various cancers, including research on cancer molecular mechanisms, screening tumor resistance associated genes and tumor gene therapy. In this review, the CRISPR/Cas9 genome editing system and its applications in urologic tumors were highlighted.

关 键 词：CRISPR/Cas9 基因编辑 泌尿系统肿瘤 基因治疗 

分 类 号：R737.1[医药卫生—肿瘤]